Comparative Pharmacology
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus NOVOCAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOSITE TOPICAL SYSTEM KIT versus NOVOCAIN.
LIDOSITE TOPICAL SYSTEM KIT vs NOVOCAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Procaine, an ester-type local anesthetic, reversibly binds to the intracellular portion of voltage-gated sodium channels, inhibiting sodium influx and blocking nerve impulse conduction.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
Local infiltration: 0.5% solution, up to 20 mL (100 mg) per dose; nerve block: 1-2% solution, 5-10 mL (50-200 mg); maximum single dose: 7 mg/kg or 350 mg (without epinephrine).
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Plasma half-life: approximately 30–60 seconds due to rapid hydrolysis by pseudocholinesterases; clinical effects short-lived.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Renal excretion of para-aminobenzoic acid (PABA) and diethylaminoethanol as major metabolites; <2% excreted unchanged in urine. Biliary/fecal: minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic